What smart money is saying about Abeona Therapeutics
1 fund in our archive has pitched Abeona Therapeutics — most recently Riverwater Micro Opportunities Strategy in June 2025.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Riverwater Micro Opportunities StrategyJune 2025
Abeona Therapeutics is a first-mover in curative gene therapies for severe rare dermatological diseases, particularly with its FDA-approved Zevaskyn, offering high efficacy in wound healing and strong market positioning despite a niche patient population.
Read the full thesis
Read every full thesis on Abeona Therapeutics
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→